<DOC>
	<DOCNO>NCT00070941</DOCNO>
	<brief_summary>This study test chemical call s-adenosyl-methionine ( SAM-e ) treatment depression patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>SAM-e Treatment Depression Patients With Parkinson 's Disease</brief_title>
	<detailed_description>PD commonly associate depression , conventional antidepressant limited efficacy patient PD may exacerbate motor symptom . SAM-e available United States food supplement promote mood enhancer . SAM-e improves dopamine transmission , may beneficial effect dopamine receptor , may good alternative currently-used antidepressant patient PD . This study investigate whether SAM-e safe effective treatment depression associate PD . The efficacy SAM-e compare placebo escitalopram , selective serotonin reuptake inhibitor commonly use treatment depression PD . Participants study randomly assign receive SAM-e , escitalopram , placebo 12 week . Some participant may choose extend treatment additional 12 week ( total 24 week study medication ) . Participants study visit entry Weeks 2 , 4 , 8 , 12 . Study visit include neurological evaluation , psychiatric evaluation , blood test , quality life questionnaire . A telephone interview conduct Week 10 .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Inclusion Criteria Idiopathic Parkinson 's disease indicate presence least two follow sign : rest tremor , rigidity , bradykinesia , postural reflex impairment Stable antiparkinson medication regimen , change medication 4 week prior study entry No antidepressant antipsychotic medication within 30 day prior study entry Agree start pharmacotherapy , psychotherapy , behavior therapy participate trial Acceptable method contraception Ability read and/or follow write oral instruction present English Sufficient cognitive ability ( baseline MiniMental Status &gt; 24 ) provide inform consent Exclusion Criteria History cardiac , hepatic , renal , hematologic , respiratory , endocrine , vascular , metabolic , system abnormality clinically relevant opinion study official Certain abnormal laboratory value Pregnant breastfeeding Use investigational drug within 3 month study entry Use St. John 's Wort `` natural '' product know mood enhance property 30 day prior study entry Selegiline monoamine oxidase inhibitor within 6 week prior study entry Regular usage antianxiety medication habitual use sleep medication , although occasional use certain hypnotic ( temazepam , melatonin , zolpidem ) allow Psychotherapy initiate 6 month prior study entry History bipolar disorder , hypomania , mania , schizophrenia , psychotic disorder Serious suicidal attempt 12 month prior study entry serious suicidal tendencies/potential Use dopamine receptor antagonist ( metoclopramide , haloperidol ) Secondary Parkinsonian symptom due drug ( include dopamine receptor antagonist ) , metabolic disorder , cerebrovascular disease , encephalitis , degenerative disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Parkinsons Disease</keyword>
	<keyword>Depression</keyword>
	<keyword>SAM-e</keyword>
</DOC>